Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 5/20 | 0.67 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.60 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.60 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.57 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.57 |
| ▸ | LTA4H | P09960 | 1/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.56 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.56 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.55 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL68789 | 0.92 | BCHE (0.65) | BCHESPHK2SPHK1FFAR1FFAR4 | |
| SCHEMBL4948686 | 0.86 | SIGMAR1 (0.62) | EPHX2NPC1RAB9ASIGMAR1 | |
| SCHEMBL7391510 | 0.83 | SPHK2 (0.82) | BCHESPHK2SPHK1PARP10 | |
| SCHEMBL15890912 | 0.83 | S1PR1 (0.82) | BCHES1PR1S1PR3LTA4HEPHX2 | |
| SCHEMBL4953206 | 0.81 | SIGMAR1 (0.61) | S1PR1S1PR3SIGMAR1 | |
| SCHEMBL11476550 | 0.80 | BCHE (1.00) | BCHELTA4HEPHX2SIGMAR1 | |
| SCHEMBL950170 | 0.80 | S1PR1 (0.82) | BCHES1PR1S1PR3LTA4HFFAR1 | |
| SCHEMBL11435183 | 0.79 | SMN1; SMN2 (0.53) | SMN1; SMN2 | |
| SCHEMBL14564669 | 0.79 | S1PR1 (0.81) | S1PR1S1PR3LTA4HFFAR1S1PR5 | |
| SCHEMBL8343327 | 0.79 | BCHE (0.70) | BCHELTA4HEPHX2FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120264823-A1 | SUBSTITUTED HETEROARYL- AND ARYL-CYCLOPROPYLAMINE ACETAMIDES AND THEIR USE | ORYZON GENOMICS S.A. | 2012-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264823-A1 | SUBSTITUTED HETEROARYL- AND ARYL-CYCLOPROPYLAMINE ACETAMIDES AND THEIR USE | CBR1, CNR1, CBR3 | BCHE 601/4885SPHK2 2041/4885SPHK1 1636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.